Brugada syndrome treatment: Difference between revisions

Jump to navigation Jump to search
Line 5: Line 5:
==Overview==
==Overview==
==Medical Therapy==
==Medical Therapy==
==Lithium Treatment and Brugada Syndrome==
===Lithium Treatment and Brugada Syndrome===
Administration of [[Lithium]] can result in EKG manifestations of the Brugada syndrome. <ref>Pirotte  MJ,  Mueller  JG,  Poprawski  T.  A case report of Brugada-type  electrocardiographic changes in a patient taking lithium. Am J Emerg Med.  2008;  26:  113.</ref><ref>Wright D, Salehian O. Brugada-Type Electrocardiographic Changes Induced by Long-Term Lithium Use. Circulation, FRCPC2010;122:e418-e419</ref>.  [[Syncope]] and [[sudden cardiac death]] have been observed in these patients.<ref>Laske  C,  Soekadar  SR,  Laszlo  R,  Plewnia  C.  Brugada syndrome in a patient treated with lithium. Am J Psychiatry.  2007;  164:  1440–1441. </ref>
Administration of [[Lithium]] can result in EKG manifestations of the Brugada syndrome. <ref>Pirotte  MJ,  Mueller  JG,  Poprawski  T.  A case report of Brugada-type  electrocardiographic changes in a patient taking lithium. Am J Emerg Med.  2008;  26:  113.</ref><ref>Wright D, Salehian O. Brugada-Type Electrocardiographic Changes Induced by Long-Term Lithium Use. Circulation, FRCPC2010;122:e418-e419</ref>.  [[Syncope]] and [[sudden cardiac death]] have been observed in these patients.<ref>Laske  C,  Soekadar  SR,  Laszlo  R,  Plewnia  C.  Brugada syndrome in a patient treated with lithium. Am J Psychiatry.  2007;  164:  1440–1441. </ref>
The putative role of [[lithium]] has been suggested in so far as withdrawal of [[lithium]] results in either 1) normalization of the ECG or 2) conversion of the Brugada pattern to type 2 or 3. The appearance of Brugada type EKG patterns does not require toxic [[lithium]] levels.
The putative role of [[lithium]] has been suggested in so far as withdrawal of [[lithium]] results in either 1) normalization of the ECG or 2) conversion of the Brugada pattern to type 2 or 3. The appearance of Brugada type EKG patterns does not require toxic [[lithium]] levels.

Revision as of 03:57, 31 August 2012

Brugada syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Brugada syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Examples of Type I Brugada Syndrome

Chest X Ray

Echocardiography or Ultrasound

Electrophysiologic Studies

Genetic Testing

Treatment

Treatment

Drugs to Avoid

Drugs to Preferably Avoid

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Brugada syndrome treatment On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Brugada syndrome treatment

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Brugada syndrome treatment

CDC on Brugada syndrome treatment

Brugada syndrome treatment in the news

Blogs on Brugada syndrome treatment

Directions to Hospitals Treating Brugada syndrome

Risk calculators and risk factors for Brugada syndrome treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Lithium Treatment and Brugada Syndrome

Administration of Lithium can result in EKG manifestations of the Brugada syndrome. [1][2]. Syncope and sudden cardiac death have been observed in these patients.[3] The putative role of lithium has been suggested in so far as withdrawal of lithium results in either 1) normalization of the ECG or 2) conversion of the Brugada pattern to type 2 or 3. The appearance of Brugada type EKG patterns does not require toxic lithium levels.

Sodium Challenge

  • Drugs that can be used
    • Ajmaline 1 mg/kg/5 min IV
    • Flecainide 2 mg/kg/10 min IV or 400 mg PO
    • Procainamide 10 mg/kg/10 min IV
    • Pilsicainide 1 mg/kg/10 min IV
  • The sodium challenge should be terminated when
  1. Diagnostic Type 1 ST-segment elevation or Brugada ECG, develops
  2. ST segment in Type 2 increases by ≥2 mm
  3. Premature ventricular beats or other arrhythmias develop
  4. QRS widens to ≥130% of baseline

References

  1. Pirotte MJ, Mueller JG, Poprawski T. A case report of Brugada-type electrocardiographic changes in a patient taking lithium. Am J Emerg Med. 2008; 26: 113.
  2. Wright D, Salehian O. Brugada-Type Electrocardiographic Changes Induced by Long-Term Lithium Use. Circulation, FRCPC2010;122:e418-e419
  3. Laske C, Soekadar SR, Laszlo R, Plewnia C. Brugada syndrome in a patient treated with lithium. Am J Psychiatry. 2007; 164: 1440–1441.

Template:WH Template:WS